Major trial tests safer drug for Kids' leukemia
NCT ID NCT00400946
Summary
This study aimed to find the best way to give a crucial drug called asparaginase to children with acute lymphoblastic leukemia (ALL). It directly compared a newer, longer-lasting version given by IV with the standard version given by injection. The main goal was to see which method caused fewer serious side effects like allergic reactions or pancreatitis, while still effectively controlling the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Albert Einstein Cancer Center at Albert Einstein College of Medicine
The Bronx, New York, 10461, United States
-
Centre de Recherche du Centre Hospitalier de l'Universite Laval
Sainte-Foy, Quebec, GIV 4G2, Canada
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Hasbro Children's Hospital
Providence, Rhode Island, 02903, United States
-
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
New York, New York, 10032, United States
-
Hopital Sainte Justine
Montreal, Quebec, H3T 1C5, Canada
-
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, 14642, United States
-
McMaster Children's Hospital at Hamilton Health Sciences
Hamilton, Ontario, L8N 3Z5, Canada
Conditions
Explore the condition pages connected to this study.